ISIS Insider Trading Activity and SEC Form 4 Filings
ISIS insider trading summary
No open-market insider purchases or sales of Isis Pharmaceuticals Inc (ISIS) have been reported on SEC Form 4 in the past 12 months.
Latest ISIS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 16, 2015 | C Frank Bennett | SVP, Antisense Research | Sell | $230K (3,909 @ $58.85) |
| Dec 15, 2015 | C Frank Bennett | SVP, Antisense Research | Sell | $224K (4,000 @ $56.00) |
| Dec 1, 2015 | Patrick R. O'Neil | SVP, Legal & General Counsel | Sell | $62K (1,000 @ $61.50) |
| Nov 11, 2015 | Joseph Klein III | Director | Sell | $241K (3,750 @ $64.18) |
| Nov 11, 2015 | Joseph Klein III | Director | Sell | $201K (3,125 @ $64.18) |
| Nov 10, 2015 | C Frank Bennett | SVP, Antisense Research | Sell | $320K (5,000 @ $64.00) |
| Nov 6, 2015 | C Frank Bennett | SVP, Antisense Research | Sell | $280K (5,000 @ $56.00) |
| Nov 3, 2015 | Patrick R. O'Neil | SVP, Legal & General Counsel | Sell | $52K (1,000 @ $51.95) |
| Oct 23, 2015 | Stanley T Crooke | Chairman and CEO | Sell | $183K (4,163 @ $43.90) |
| Oct 23, 2015 | Stanley T Crooke | Chairman and CEO | Sell | $88K (2,000 @ $44.17) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.